New Oncology and Gustave Roussy collaborate on genetic testing
14 October 2014
Cologne-based cancer diagnostics developer New Oncology has
announced that it has entered into a collaboration agreement with
Gustave Roussy Cancer Campus, a research institute based in Paris.
Under this agreement, New Oncology will perform comprehensive
parallel multigene testing to identify therapeutically relevant
alterations in cancer-related genes. New Oncology will apply its
proprietary diagnostic platform ‘NEO’, which allows rapid sample
processing compatible with both daily clinical routine and standard
sample material, ie FFPE (formalin-fixed, paraffin-embedded) tissue.
No financial details were disclosed.
“We are very pleased to partner with Gustave Roussy, Europe’s
leading oncology center. We look forward to contributing New
Oncology’s unique diagnostic platform enabling in-depth genetic
profiling of tumour samples. Together, we expect to significantly
improve personalized approaches for the benefit of cancer patients”
commented Dr. Andreas Jenne, CEO of New Oncology.
“The dramatic responses seen in patients receiving targeted
treatment have shifted the therapeutic paradigm to therapies which
are based on the molecular characteristics of a given cancer. Thus,
comprehensive genomic diagnosis of FFPE tissues is an important step
to optimize clinical care to patients throughout the different lines
of therapy” said Professor Jean-Charles Soria, Head of the Drug
Development Department at Gustave Roussy Cancer Campus.
Source: New Oncology press release.